Penn Myeloproliferative Neoplasms Case Conference 2016-2017

Penn Myeloproliferative Neoplasms Case Conference 2016-2017

Penn Myeloproliferative Neoplasms Case Conference 2016-2017

Sessions

Topic Session datesort icon
Management of portal Hypertension in Myeloproliferative Neoplasms 1/13/16
The Role of GSK-3 MPN and Leukemia 1/27/16
"The genomic landscape of juvenile myelomonocytlic leukemia" 3/2/16
"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition" 3/9/16
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms 3/30/16
"Dominant gain-of-function mutation in tyrosine kinase SRC causes thrombocytopenia, myelobibrosis, bleeding, and bone pathologies" 4/6/16
"Acquired Myeloperoxidase (MPO) Deficiency in Patients with Myelofibrosis is Caused by Homozygous CALR mutations" 4/13/16
"Leukemia-specific dependence on circadian clock genes" 4/20/16
"CMML Basics: Approach to Diagnosis and Therapy in 2016" 4/27/16
"The connection between Asxl1 mutation and Polycomb histone marks" 5/4/16
"Hypomethylating agents restore balanced hematopoiesis in CMML without decreasing the size of the muated clone" 5/11/16
"How normal ABL1 acts as a tumor suppressor in CML" 5/18/16
"In low-risk, CALR-mutated ET, aspirin does not reduce the risk of thrombosis and may increase the risk of bleeding" 5/25/16
"The significance of additional cytogenetic abnormalities in CML" 6/8/16
"Danazol Treatment for Telomere Diseases" 6/15/16
"The Genomic Classification and Prognosis in Acute Myeloid Leukemia" 6/22/16
"Role of the HMGA2 Gene in Myeloproliferative Neoplasms and Normal Hematopoiesis" 7/6/16
"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis" 7/13/16
"Eradicating CML stem cell by Bcl-2 inhibition" 10/5/16
"A role for cancer immunotherapy for CALR mutation-positive MPN” 10/12/16
"Long Term Durability of Ruxolitinib for Myelofribrosis" 11/2/16
"The New NCCN Guidelines for Myeloproliferative Neoplasms" 11/16/16
"Updates on myeloproliferative neoplasms from the American Society of Hematology Annual Meeting" 12/14/16
Updates on Ruxolitinib in PV and MPN-related complications: RESPONSE-2, RELIEF, and Splanchnic vein thrombosis" 1/18/17
"Dnmt3a mutations and anthracycline resistance" 1/25/17
New Therapeutic Advances for Systemic Mastocytosis in 2016 3/1/17
"Clonal hematolopoiesis causes atherosclerosis" 3/8/17
"2017 CML Updates" 3/15/17
Exh2 loss induces drug resistance in AML 4/26/17
"Eltrombopag as a first-line agent in aplastic anemia" 5/3/17
"Targeting the spliceosome in myeloid malignancies" 5/17/17
Clinical Topics in MPN: Contemporary use of platelet pheresis for management of extreme thrombocytosis & Diagnostic value of serum erythropoietin in PV 5/24/17
"Polymerase I inhibition as a strategy for AML treatment" 5/31/17
Office of Continuing Medical and Interprofessional Education
150 Anatomy/Chemistry Building, 3620 Hamilton Walk
Philadelphia, PA 19104-6061
Contact us: penncme@mail.med.upenn.edu | 215-898-8005
© The Trustees of the University of Pennsylvania
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.